Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK0529 in 2–5 year-old children with RSV infection
CTR20223276Phase 2Completed
- Sponsor
- Aicobio
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ziresovir in respiratory syncytial virus disease (RSV), sponsored by Aicobio. Primary endpoint: AK0529 plasma concentration and pharmacokinetic parameters. Started Jan 2023; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20223276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223276.